1. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 7 (July 2018) Authors: Clarke, Noel; Wiechno, Pawel; Alekseev, Boris; Sala, Nuria; Jones, Robert; Kocak, Ivo; Chiuri, Vincenzo Emanuele; Jassem, Jacek; Fléchon, Aude; Redfern, Charles; Goessl, Carsten; Burgents, Joseph; Kozarski, Robert; Hodgson, Darren; Learoyd, Maria; Saad, Fred Journal: Lancet oncology Issue: Volume 19:Issue 7(2018) Page Start: 975 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Issue 10 (October 2022) Authors: Saad, Fred; Thiery-Vuillemin, Antoine; Wiechno, Pawel; Alekseev, Boris; Sala, Nuria; Jones, Robert; Kocak, Ivo; Chiuri, Vincenzo Emanuele; Jassem, Jacek; Fléchon, Aude; Redfern, Charles; Kang, Jinyu; Burgents, Joseph; Gresty, Christopher; Degboe, Arnold; Clarke, Noel W Journal: Lancet oncology Issue: Volume 23:Issue 10(2022) Page Start: 1297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗